0LW1 Stock Chart & Stats
€0.01
--
Market closed
€0.01
--
Day’s Range― - ―
52-Week Range€0.11 - €6,200.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.46K
Market Cap
€66.81K
Enterprise Value€3.26K
Total Cash (Recent Filing)€571.79K
Total Debt (Recent Filing)€537.20K
Price to Earnings (P/E)―
Beta14.21
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding159,064
10 Day Avg. Volume1,020
30 Day Avg. Volume1,457
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces refinancing pressure and preserves flexibility to fund research or restructure operations. This is only a relative strength: it does not offset losses, but it gives the company more balance-sheet capacity than a highly indebted biotech.
Improved Cash BurnThe 2025 improvement means cash consumption was less severe than in the prior year, potentially extending financial runway. However, because operating and free cash flow remain negative, this is a modest stabilizing factor rather than evidence of self-funding.
Kinoid Platform PotentialThe Kinoid platform is designed to induce antibodies against defined targets and potentially create durable immune responses. That mechanism can support differentiated partnering or licensing opportunities, although the pack confirms no current commercial partner or revenue.
Bears Say
Sharp Revenue DeclineRevenue fell about 44% in 2025 after inconsistent sales across prior years, signaling limited commercial scale. Sustained revenue weakness makes it harder to absorb fixed R&D costs and increases dependence on future partnerships, milestones, or financing.
Persistent UnprofitabilityNegative gross profit in most years and persistent operating losses, including very large negative margins in 2025, show that current activities do not cover their cost base. Without operating leverage or successful commercialization, losses may continue eroding equity.
Ongoing Cash DependenceOperating and free cash flow were negative in every year shown, including 2025. The company therefore is not self-funding and may need external capital over time, creating dilution or execution risk unless revenue rises or costs fall materially.
0LW1 FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €0.11 and its highest was €6200.00 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €66.81K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Mar 30, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 159,064 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -28%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in DE:0LW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.